True regarding Denosumab
Denosumab, an antibody that blocks the RANK ligand (RANKL) and dramatically reduces osteoclast number and function, is approved for therapy of osteoporosis. It also appears to be an effective treatment to reverse hypercalcemia of malignancy. Jaw necrosis, atypical femoral fracture, skin infections , occasional severe hypocalcemia are the side effects. Ref Harrison 20th edi page no 2956
Strong antiresorptive action
Binds RANKL & prevents its binding to receptor RANK
Atypical femoral fracture as one of the adverse effects
All of the above
Endocrinology